Retatrutide in 2026: what the phase 3 numbers mean
Why TRIUMPH-1 reports both 25.0% and 28.3% weight loss, what its safety findings show, and how those results differ from FDA approval.
Follow a thread
Metabolic health
2 stories found Clear filters ↗
The archive
2 storiesMetabolic health
GLP-1 and GIP: reading the semaglutide–tirzepatide comparison
A receptor count cannot rank a medicine. Current US labels and the SURMOUNT-5 trial show why product, population and outcome must stay attached to every comparison.